# SCDM.CCDM.v2026-02-03.q51

| | |
|---|---|
| **Exam Code:** | CCDM |
| **Exam Name:** | Certified Clinical Data Manager |
| **Certification Provider:** | SCDM |
| **Free Question Number:** | 51 |
| **Version:** | v2026-02-03 |
| **# of views:** | 117 |
| **# of Questions views:** | 510 |
| https://www.freeqas.com/qa/SCDM/CCDM/SCDM.CCDM.v2026-02-03.q51.html | |

**NEW QUESTION: 1**
Which is the best reason why front-end checks are usually kept minimal, when compared to back-end checks, in a paper-based clinical study?
**A.** Data entry staff should be able to enter a value into the database just as it appears in the paper CRF
**B.** There is no need to alert the site personnel immediately about a data issue, as the study has happened already
**C.** There are approvals required to raise a Data Clarification Form which could take time
**D.** Data review can be performed at a later time due to the paper-based studies being smaller in size
**Answer: A (LEAVE A REPLY)**
In paper-based clinical studies, front-end data checks (those performed during data entry) are intentionally kept minimal to ensure that data are entered exactly as recorded on the paper CRF. This principle ensures data integrity by maintaining fidelity between source and electronic records before any cleaning or edit validation occurs.
The GCDMP (Chapter: Data Validation and Cleaning) explains that data entry operators should input values as written, even if they appear incorrect or inconsistent, because the purpose of front-end checks is not to interpret but to capture data faithfully. The back-end edit checks-performed later by data managers-are designed to identify inconsistencies, out-of-range values, or logical errors that require clarification through queries.
This approach separates data capture from data cleaning, minimizing bias and preserving original investigator input. Hence, option A accurately states the rationale for keeping front-end checks minimal in paper-based studies.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Validation and Cleaning, Section 4.2 - Data Entry, Edit Checks, and Query Process ICH E6(R2) GCP, Section 5.5.3 - Data Handling and System

Controls FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.1 - Data Entry and Verification Processes

**NEW QUESTION: 2**
Which of the following SOPs are required for management of an EDC system?
**A.** Management of vendors
**B.** Measurement of data quality
**C.** Maintenance of coding dictionaries
**D.** Change control
**Answer: D (LEAVE A REPLY)**
The most essential Standard Operating Procedure (SOP) for management of an Electronic Data Capture (EDC) system is Change Control.
Per GCDMP (Chapter: Computerized Systems and Compliance) and FDA 21 CFR Part 11, any changes made to an EDC system-whether to software configuration, study database design, or system functionality-must follow a documented, validated, and auditable change control process. This ensures that:
Modifications are properly authorized, tested, and approved before implementation.
System validation remains intact.
Data integrity, traceability, and regulatory compliance are maintained.
While vendor management (A) and coding maintenance (C) have supporting SOPs, change control (D) is mandatory for any system handling regulated clinical data.
Measurement of data quality (B) is important but not specifically tied to system management procedures.
Thus, option D (Change control) is the correct answer.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Computerized Systems and Compliance, Section 5.3 - Change Control and System Maintenance FDA 21 CFR Part 11 - Electronic Records and Electronic Signatures, Section 11.10(a-k) ICH E6(R2) GCP, Section 5.5.3 - Computerized Systems Validation and Change Documentation

**NEW QUESTION: 3**
A sponsor may transfer responsibility for any or all of their obligations to a contract research organization. Which of the following statements is true?
**A.** Any written description is not transferred to the contract research organization.
**B.** A description of each of the obligations being assumed by the contract research organization is required.
**C.** A description of each of the obligations being transferred to the contract research organization is not required.
**D.** A general statement that all obligations have been transferred is acceptable.
**Answer: B (LEAVE A REPLY)**

Under ICH E6 (R2) Good Clinical Practice and 21 CFR Part 312.52, when a sponsor delegates or transfers obligations for a clinical trial to a Contract Research Organization (CRO), there must be a written description of each specific obligation being assumed by the CRO.
According to the Good Clinical Data Management Practices (GCDMP), while sponsors may outsource responsibilities such as data management, monitoring, or biostatistics, ultimate accountability remains with the sponsor. The documentation of the transfer of responsibilities ensures regulatory transparency and compliance.
This written agreement, often referred to as a Transfer of Obligations (TOO) document, defines exactly which duties the CRO is responsible for (e.g., CRF design, data cleaning, database lock), as well as any retained sponsor oversight. A general statement that "all obligations are transferred" (option D) is insufficient per regulatory expectations, as sponsors must retain traceability of responsibility.
Therefore, Option B is correct - a detailed written description of transferred obligations is required.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Regulatory Compliance and Oversight, Section 5.2 - Sponsor and CRO Responsibilities ICH E6 (R2) Good Clinical Practice, Section 5.2.1 - Transfer of Trial-Related Duties and Functions FDA 21 CFR 312.52 - Transfer of Obligations to a Contract Research Organization

**NEW QUESTION: 4**
Which metric reveals the timeliness of the site-work dimension of site performance?
**A.** Time from Last Patient Last Visit to database lock
**B.** Time from final protocol to first patient enrolled
**C.** Time from site contract execution to first patient enrolled
**D.** Median and range of time from query generation to resolution
**Answer: D (LEAVE A REPLY)**
The site-work dimension of site performance evaluates how efficiently sites manage and resolve data-related tasks - particularly query resolution, data entry, and correction timelines. Among the given metrics, the median and range of time from query generation to resolution (D) directly measures the site's responsiveness and data management efficiency.
According to the GCDMP (Chapter on Metrics and Performance Measurement), this indicator helps identify sites that delay query resolution, which can impact overall study timelines and data quality. Tracking this metric allows the data management team to proactively provide additional training or communication to underperforming sites.
Other options measure different aspects of project progress:
A reflects overall database closure speed.
B and C relate to study startup and enrollment readiness, not ongoing data work.

Thus, option D accurately represents a site performance timeliness metric, aligning with CCDM principles for operational performance measurement.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Metrics and Performance Management, Section 5.4 - Site Query Resolution Metrics ICH E6(R2) Good Clinical Practice, Section 5.18 - Monitoring and Site Performance Oversight

**NEW QUESTION: 5**
Which type of edit check would be implemented to check the correctness of data present in a text box?
**A.** Manual Check
**B.** Back-end check
**C.** Front-end check
**D.** Programmed check
**Answer: C (LEAVE A REPLY)**
A front-end check is a type of real-time validation performed at the point of data entry-typically within an Electronic Data Capture (EDC) system or data entry interface-designed to ensure that the data entered in a text box (or any input field) is valid, logically correct, and within expected parameters before the user can proceed or save the record.
According to the Good Clinical Data Management Practices (GCDMP, Chapter on Data Validation and Cleaning), edit checks are essential components of data validation that ensure data accuracy, consistency, and completeness. Front-end checks are implemented within the data collection interface and are triggered immediately when data are entered. They prevent invalid entries (such as letters in numeric fields, out-of-range values, or improper date formats) from being accepted by the system.
Examples of front-end checks include:
Ensuring a numeric field accepts only numbers (e.g., weight cannot include text characters).
Validating that a date is within an allowable range (e.g., not before the subject's date of birth).
Requiring mandatory fields to be completed before moving forward.
This differs from back-end checks or programmed checks, which are typically run later in batch processes to identify data inconsistencies after entry. Manual checks are human-performed reviews, often for context or data that cannot be validated automatically (e.g., narrative assessments).
Front-end edit checks are preferred wherever possible because they prevent errors at the source, reducing the number of downstream data queries and cleaning cycles. They contribute significantly to data quality assurance, regulatory compliance, and efficiency in data management operations.
Reference (CCDM-Verified Sources):

Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 6.2 - Edit Checks and Real-Time Data Validation FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6 - Data Entry and Verification Controls ICH E6 (R2) Good Clinical Practice, Section 5.5 - Data Handling and Record Integrity CDISC Operational Data Model (ODM) Specification - Edit Check Implementation Standards

**NEW QUESTION: 6**
For clinical investigational sites on an EDC trial, which of the following archival options allows traceability of changes made to data?
**A.** Storing the computer used at the clinical investigational site
**B.** Paper copies of the source documents
**C.** PDF images of the final eCRF screens for each patient
**D.** ASCII files of the site's data and related audit trails
**Answer: D (LEAVE A REPLY)**
Regulatory agencies such as the FDA and ICH require that electronic data be retained in a format that preserves audit trails and traceability.
While PDF images (option C) provide a static representation of data, they do not preserve the underlying audit trail (i.e., who changed what, when, and why). The ASCII data files with corresponding audit trails (option D) provide complete transparency and comply with 21 CFR Part 11 and GCDMP archival standards.
Option A (storing computers) is unnecessary and impractical, and Option B (paper source documents) are site records, not system archives.
Hence, option D is correct - ASCII data files with audit trails meet traceability and compliance standards.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Lock and Archiving, Section 5.4 - Archival Formats and Audit Trail Retention ICH E6(R2) GCP, Section 5.5.3 - Data Integrity, Audit Trails, and Record Retention FDA 21 CFR Part 11 - Electronic Records; Audit Trail and Retention Requirements

**NEW QUESTION: 7**
Which of the following data verification checks would most likely be included in a manual or visual data review step?
**A.** Checking an entered value against a valid list of values
**B.** Checking adverse event treatments against concomitant medications
**C.** Checking mandatory fields for missing values
**D.** Checking a value against a reference range
**Answer: B (LEAVE A REPLY)**
Manual or visual data review is used to identify complex clinical relationships and contextual inconsistencies that cannot be detected by automated edit checks.

According to the GCDMP (Chapter: Data Validation and Cleaning), automated edit checks are ideal for structured validations, such as missing fields (option C), reference ranges (option D), or predefined value lists (option A). However, certain clinical cross-checks-such as verifying adverse event treatments against concomitant medication records-require clinical judgment and contextual understanding.
For example, if an adverse event of "severe headache" was reported but no analgesic appears in the concomitant medication log, the data may warrant manual review and query generation. These context-based checks are best performed by trained data reviewers or medical data managers during manual data review cycles.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 6.3 - Manual Review and Clinical Data Consistency Checks ICH E6 (R2) Good Clinical Practice, Section 5.18.4 - Clinical Data Review Responsibilities FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations - Data Verification Principles

**NEW QUESTION: 8**
What significant difference is there in the DM role when utilizing an EDC application?
**A.** Data updates are implemented by the sites
**B.** Database validation is not required
**C.** Metrics generation is required
**D.** Tracking of eCRFs is a monitor's responsibility
**Answer: (SHOW ANSWER)**
The most significant difference in the Data Manager's role when using an Electronic Data Capture (EDC) system is that data updates are implemented directly by site personnel (Option A).
According to the GCDMP (Chapter: Electronic Data Capture Systems), EDC technology shifts responsibility for data entry and correction from the sponsor or CRO to the investigator site, enabling real-time data entry and validation. This eliminates the need for double entry or remote data transcription, allowing Data Managers to focus on system validation, query management, and data quality oversight rather than physical data handling.
However, the EDC system still requires full validation (contrary to Option B). Metrics generation (Option C) and CRF tracking (Option D) are important but not unique to EDC-based workflows.
Thus, the correct answer is Option A - Data updates are implemented by the sites, reflecting the most fundamental operational shift introduced by EDC systems.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Electronic Data Capture (EDC) Systems, Section 4.1 - Role of the Data Manager in EDC ICH E6 (R2)

GCP, Section 5.5.3 - Electronic Data Entry and Responsibilities FDA 21 CFR Part 11 - Electronic Records and Signatures: Data Entry Responsibilities

**NEW QUESTION: 9**
A study numbers subjects sequentially within each site and does not reuse site numbers. Which information is required when joining data across tables?
**A.** Subject number and site number
**B.** Subject number
**C.** Study number and subject number
**D.** Site number
**Answer: A (LEAVE A REPLY)**
When subjects are numbered sequentially within each site, it means that the subject identification numbers (Subject IDs) restart from 001 at each site. For example, Site 101 may have Subject 001, and Site 102 may also have a Subject 001. In such cases, the subject number alone is not globally unique across the entire study. Therefore, when integrating or joining data across multiple database tables (for example, linking demographic, adverse event, and laboratory data), both the site number and the subject number are required to create a unique key that accurately identifies each record.
According to the Good Clinical Data Management Practices (GCDMP, Chapter on CRF Design and Data Collection), every data record in a clinical trial database must be uniquely and unambiguously identified. This is typically achieved through a composite key, combining identifiers such as site number, subject number, and sometimes study number. The GCDMP specifies that a robust data structure must prevent duplication or mislinking of records across domains or tables.
Furthermore, FDA and CDISC standards (SDTM model) also emphasize the importance of unique subject identifiers (USUBJID), which are derived from concatenating the study ID, site ID, and subject ID. This ensures traceability, integrity, and accuracy of subject-level data during database joins, data exports, and regulatory submissions.
Thus, in the described scenario, since subject numbering restarts at each site, both the site number and subject number are required to uniquely identify and correctly join subject data across different datasets or tables.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: CRF Design and Data Collection, Section 4.1 - Unique Subject Identification CDISC SDTM Implementation Guide, Section 5.2 - Subject and Site Identification (Variable: USUBJID) FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6 - Data Integrity and Record Identification

**NEW QUESTION: 10**
According to ICH E6, developing a Monitoring Plan is the responsibility of whom?
**A.** Sponsor

**B.** CRO
**C.** Data Manager
**D.** Monitor
**Answer: A (LEAVE A REPLY)**
According to ICH E6(R2) Good Clinical Practice (GCP), Section 5.18.1, the Sponsor is ultimately responsible for developing and implementing the Monitoring Plan.
The Monitoring Plan defines:
The extent and nature of monitoring (e.g., on-site, remote, risk-based).
The responsibilities of monitors.
The communication and escalation procedures for data quality and protocol compliance.
While the CRO (B) or Monitor (D) may perform monitoring activities under delegation, the Sponsor retains legal accountability for ensuring a compliant and effective plan is developed and maintained. The Data Manager (C) may contribute by outlining data review workflows, but is not responsible for authoring or owning the plan.
Therefore, option A (Sponsor) is the correct answer.
Reference (CCDM-Verified Sources):
ICH E6(R2) GCP, Section 5.18.1 - Purpose and Responsibilities for Monitoring SCDM GCDMP, Chapter: Regulatory Compliance and Oversight, Section 5.3 - Sponsor Responsibilities in Monitoring and Quality Assurance FDA Guidance for Industry: Oversight of Clinical Investigations - Sponsor Responsibilities (2013)

**NEW QUESTION: 11**
Which document describes what study subjects expect with respect to data disclosure during and after a study?
**A.** Study data sharing plan
**B.** ICH essential documents
**C.** Informed consent form
**D.** Study protocol
**Answer: C (LEAVE A REPLY)**
The Informed Consent Form (ICF) is the document that explicitly describes what study subjects can expect regarding data disclosure, privacy, and confidentiality during and after participation in a clinical trial. According to ICH E6 (R2) Good Clinical Practice and FDA Human Subject Protection Regulations (21 CFR Parts 50 and 56), participants must be fully informed about how their personal and clinical data will be collected, used, stored, and shared - both during the study and in any subsequent data-sharing or publication activities.
The GCDMP reiterates that clinical data managers must ensure that all data handling practices align with the privacy commitments made in the ICF. This includes compliance with data protection regulations such as HIPAA (in the U.S.) and GDPR (in the EU). The ICF defines the permissible scope of data use, ensuring ethical management and subject protection.

Documents like the protocol or data sharing plan may outline procedures and responsibilities but do not directly inform participants of their rights and data use expectations. Only the ICF is designed for that ethical communication purpose.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Ethics, Privacy, and Data Security ICH E6 (R2) Good Clinical Practice, Sections 4.8.10 & 4.8.12 FDA 21 CFR Part 50 - Protection of Human Subjects, Informed Consent Requirements

**NEW QUESTION: 12**
An organization conducts over fifty studies per year. Currently each study is specified and set-up from scratch. Which of the following organizational infrastructure options would streamline database set-up and study-to-study consistency?
**A.** Adopting an ODM compliant database system
**B.** Maintaining a library of form or screen modules
**C.** Improving the form or screen design process
**D.** Implementing controlled terminology for adverse events
**Answer: (SHOW ANSWER)**
To improve efficiency and ensure consistency across multiple studies, the most effective infrastructure solution is to maintain a centralized library of standardized forms or screen modules (e.g., CRF/eCRF templates).
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Database Design and Build), using a form library allows reuse of validated data collection modules for commonly collected domains such as demographics, adverse events, and vital signs. This reduces database setup time, enhances uniformity in data definitions, and ensures alignment with standards such as CDISC CDASH and SDTM.
While adopting ODM (A) provides standardized data exchange and interoperability, it does not inherently reduce setup workload. Improving design processes (C) enhances efficiency but doesn't guarantee consistency, and implementing controlled terminology (D) helps with coding standardization, not database structure.
Therefore, option B - maintaining a library of form or screen modules - provides the most direct and sustainable improvement for scalability and quality.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Design and Build, Section 5.3 - Use of Standard Libraries and Templates CDISC CDASH Implementation Guide, Section 3.2 - Reusable CRF Modules and Standardization ICH E6(R2) GCP, Section 5.5.3 - Standardization and Reuse in Data Collection Systems

**NEW QUESTION: 13**
A Clinical Data Manager is drafting data element definitions for a new study. One of the definitions provided is:

"Baby's crown to heel length measured lying on back, measured physical quantity, precision of 0.1." Which of the following is missing from the definition?

**A.** Discrete values for a drop-down list

**B.** Enumeration

**C.** Data type of the data element

**D.** Unit or dimensionality of measure

**Answer: D (LEAVE A REPLY)**

A complete data element definition in clinical data management should include:

Name and clear description of the data element,

Data type (e.g., numeric, text, date),

Precision or scale (if numeric), and

Unit or dimensionality of measure (e.g., centimeters, inches).

In this example, while the data type ("measured physical quantity") and precision (0.1) are defined, the unit of measurement (e.g., centimeters or inches) is missing. This omission leads to ambiguity and could cause serious discrepancies when comparing or analyzing measurements.

The GCDMP (Chapter: Database Design and Build) emphasizes that units and dimensionality must be explicitly defined and consistently applied in all CRFs, metadata dictionaries, and data transformations.

Thus, option D (Unit or dimensionality of measure) is correct.

Reference (CCDM-Verified Sources):

SCDM GCDMP, Chapter: Database Design and Build, Section 5.2 - Metadata and Data Element Definitions CDISC CDASH Implementation Guide, Section 3.3 - Data Element Metadata Requirements ICH E6(R2) GCP, Section 5.5.3 - Data Accuracy and Standardized Definitions

**NEW QUESTION: 14**

Which is the most important reason for why a data manager would review data before a monitor reviews it?

**A.** Data managers write the Data Management Plan that specifies the data cleaning workflow.

**B.** Data can be viewed and discrepancies highlighted prior to a monitor's review.

**C.** Data managers have access to programming tools to identify discrepancies.

**D.** The GCDMP recommends that data managers review data prior to a monitor's review.

**Answer: B (LEAVE A REPLY)**

The primary reason data managers review data before a monitor's review is to identify and flag discrepancies or inconsistencies so that site monitors can focus their efforts more efficiently during on-site or remote source data verification (SDV).

According to the Good Clinical Data Management Practices (GCDMP, Chapter on Data Validation and Cleaning), proactive data review by data management staff ensures data completeness and accuracy by identifying missing, inconsistent, or out-of-range values.

This pre-review helps streamline the monitoring process, reduces the volume of open queries, and enhances data quality.
Option A is true but not the main reason for pre-monitor review. Option C highlights a capability rather than a rationale. Option D is partially correct, but the GCDMP emphasizes process purpose, not prescriptive order. Thus, option B correctly captures the practical and process-oriented reason for early data review-to ensure data are ready and accurate for the monitor's review phase.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Validation and Cleaning, Section 5.3 - Data Review Timing and Purpose ICH E6(R2) GCP, Section 5.18 - Monitoring and Data Verification Requirements

**NEW QUESTION: 15**
A study has an expected enrollment period of one year but has subject recruitment issues. Twelve new sites are added toward the end of the expected enrollment period to help boost enrollment. What is the most likely impact on data flow?
**A.** Additional sites will likely have increased query rates since site training is occurring closer to study close.
**B.** A bolus of CRFs at the end of the study will result in the need to increase data entry and cleaning rates to meet existing timelines.
**C.** The distribution of subjects selected for quality control will need to be stratified to allow for the twelve new sites.
**D.** The database set-up will need to be changed to allow for additional sites as they are added to the study.
**Answer: (SHOW ANSWER)**
Adding multiple new sites late in the enrollment period creates a concentrated influx of new data near the end of the study. These sites typically start enrolling patients later, resulting in a "bolus" of Case Report Forms (CRFs) that must be entered, validated, and cleaned within a shorter timeframe to meet database lock deadlines.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Project Management and Data Flow), late site activation compresses the timeline for data management tasks, necessitating increased resources for data entry, query management, and cleaning. Data management teams must anticipate this surge and plan accordingly-either by increasing staffing or revising timelines to prevent bottlenecks and maintain quality.
While option D (increased query rates) can occur, it is a secondary effect. The most direct and consistent impact is the surge in data volume requiring expedited processing near study end.
Reference (CCDM-Verified Sources):

SCDM GCDMP, Chapter: Project Management, Section 5.3 - Managing Changes in Site Activation and Data Flow ICH E6(R2) GCP, Section 5.1 - Quality Management and Oversight

**NEW QUESTION: 16**
When a data manager runs a report on resolution types of discrepancy status, which of the following would NOT be a part of resolution types?
**A.** Cannot be resolved (but data incorrect)
**B.** Received from site and not yet reviewed
**C.** Resolved with data/confirmed as is (non problematic)
**D.** Data management - self evident corrections
**Answer: B (LEAVE A REPLY)**
In a discrepancy management workflow, "Received from site and not yet reviewed" is not a resolution type - it represents a status, not a final resolution outcome.
According to the GCDMP (Chapter: Data Validation and Cleaning), resolution types describe how a data discrepancy was finalized or addressed, such as:
Resolved with data correction,
Confirmed as correct (no change required),
Self-evident correction applied by data management, or
Unresolvable discrepancies documented.
In contrast, statuses describe the stage of the query (e.g., open, sent, answered, pending review, closed). "Received from site and not yet reviewed" indicates an intermediate workflow state where the response awaits validation by data management.
Proper classification of resolution types is essential for performance reporting, audit readiness, and ensuring the traceability of query management actions under ICH E6 (R2) and FDA 21 CFR Part 11.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 5.3 - Discrepancy Resolution Lifecycle ICH E6 (R2) Good Clinical Practice, Section 5.5.3 - Data Handling and Record Management FDA 21 CFR Part 11 - Electronic Records; Audit Trails and Discrepancy Tracking Requirements

**Valid CCDM Dumps** shared by PrepPdf.com for Helping Passing CCDM Exam! PrepPdf.com now offer the **newest CCDM exam dumps**, the PrepPdf.com CCDM exam **questions have been updated** and **answers have been corrected** get the **newest** PrepPdf.com CCDM dumps with Test Engine here: https://www.preppdf.com/SCDM/CCDM-prepaway-exam-dumps.html (**152** Q&As Dumps, **40%OFF** **Special Discount:** **Exam-Tests**)

**NEW QUESTION: 17**
In a physical therapy study, range of motion is assessed by a physical therapist at each site using a study-provided goniometer. Which is the most appropriate quality control method for the range of motion measurement?
**A.** Programmed edit checks to detect out-of-range values upon data entry
**B.** Independent assessment by a second physical therapist during the visit
**C.** Reviewing data listings for illogical changes in range of motion between visits
**D.** Comparison to the measurement from the previous visit
**Answer: B (LEAVE A REPLY)**
In this scenario, the variable of interest-range of motion (ROM)-is a clinically measured, observer-dependent variable. The accuracy and reliability of such data depend primarily on the precision and consistency of the measurement technique, not merely on data entry validation. Therefore, the most appropriate quality control (QC) method is independent verification of the measurement by a second qualified assessor during the visit (Option D).
According to the Good Clinical Data Management Practices (GCDMP, Chapter on Data Quality Assurance and Control), quality control procedures must be tailored to the nature of the data. For clinically assessed variables, especially those involving human judgment (e.g., physical measurements, imaging assessments, or subjective scoring), real-time verification by an independent qualified assessor ensures that data are valid and reproducible at the point of collection. This approach directly addresses measurement bias, observer variability, and instrument misuse, which are primary sources of data error in clinical outcome assessments.
Other options, while valuable, address only data consistency or plausibility after collection:
Option A (comparison to previous visit) and Option C (reviewing data listings) are retrospective data reviews, suitable for identifying trends but not preventing measurement error.
Option B (programmed edit checks) detects only extreme or impossible values, not measurement inaccuracies due to technique or observer inconsistency.
The GCDMP and ICH E6 (R2) Good Clinical Practice guidelines emphasize that data quality assurance should begin at the source, through standardized procedures, instrument calibration, and dual assessments for observer-dependent measures. Having an independent second assessor ensures inter-rater reliability and provides direct confirmation that the recorded value reflects an accurate and valid measurement.
Reference (CCDM-Verified Sources):
Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and Control, Section 7.4 - Measurement Quality and Verification ICH E6 (R2) Good Clinical Practice, Section 2.13 - Quality Systems and Data Integrity FDA Guidance for Industry: Patient-Reported Outcome Measures and Clinical Outcome Assessment Data, Section 5.3 - Quality Control of Clinician-Assessed Data SCDM GCDMP Chapter: Source Data Verification and Quality Oversight Procedures

**NEW QUESTION: 18**
Electronic submission standards require that an individual subject's complete CRF should be provided as what type of file:
**A.** Portable Document Format (.pdf)
**B.** Rich Text Format (.rtf)
**C.** Microsoft Word (.docx)
**D.** Statistical Analysis System (.sas)
**Answer: A (LEAVE A REPLY)**
Electronic submission standards, as established by FDA, CDISC, and ICH, require that an individual subject's complete Case Report Form (CRF) be submitted as a Portable Document Format (.pdf) file. The PDF format is universally recognized and accepted because it ensures that the structure, format, and visual fidelity of the CRF are preserved exactly as originally designed, regardless of software or hardware environment.
According to the FDA Guidance for Industry: Providing Regulatory Submissions in Electronic Format (2006) and CDISC SDTM standards, sponsors must include a subject-level CRF in PDF form for each participant in the submission dataset. This requirement ensures that reviewers can trace data points from analysis datasets back to their source entries in the CRF, fulfilling the principles of data traceability and transparency.
The Good Clinical Data Management Practices (GCDMP) also support this requirement, emphasizing that CRF archiving should maintain readability and regulatory accessibility. Formats like RTF, DOCX, or SAS datasets are not acceptable substitutes for regulatory CRF submission because they may alter formatting, structure, or introduce modifiable content, violating FDA data integrity principles.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Archiving and Submission FDA Guidance for Industry: Providing Regulatory Submissions in Electronic Format, April 2006 CDISC SDTM Implementation Guide, Section 5.3 - CRF Representation and Traceability

**NEW QUESTION: 19**
If a data manager generated no additional manual queries on data in an EDC system and the data were deemed clean, why could the data appear to be not clean during the next review?
**A.** The study coordinator can change the data due to re-review of the source.
**B.** The CRA can change the data during a quality review of source to database.
**C.** The medical monitor can override safety information entered in the system.
**D.** The data manager may have accidentally changed the data.
**Answer: A (LEAVE A REPLY)**
In an Electronic Data Capture (EDC) system, even after a data manager completes all manual queries and marks data as "clean," the data may later appear unclean if the site

(study coordinator) makes subsequent updates in the system after re-reviewing the source documents.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Electronic Data Capture Systems), site users maintain the authority to modify data entries as long as the system remains open for data entry. The EDC system audit trail captures such changes, which can automatically invalidate prior data reviews, triggering new discrepancies or changing system edit-check statuses.
This situation commonly occurs when the site identifies corrections in the source (e.g., wrong date or lab result) and updates the EDC form accordingly. These post-cleaning changes require additional review cycles to ensure the database reflects accurate and verified information before final lock.
Options B, C, and D are incorrect - CRAs and medical monitors cannot directly change EDC data; they can only raise queries or request updates.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Electronic Data Capture Systems, Section 6.3 - Post-Cleaning Data Changes and Audit Trails ICH E6 (R2) GCP, Section 5.5.3 - Data Integrity and Change Control FDA 21 CFR Part 11 - Electronic Records: Change Documentation Requirements

**NEW QUESTION: 20**
All of the following are preparation processes the data manager needs to take prior to database closure EXCEPT:
**A.** Checking for uncoded terms in all panels that are coded.
**B.** Ensuring all data expected for the study has been received.
**C.** Performing SAE reconciliation between the clinical and safety databases.
**D.** Ensuring study close out visits have been complete.
**Answer: D (LEAVE A REPLY)**
Before database lock, the Data Manager must confirm that all collected data are complete, validated, and reconciled across systems. This includes:
Ensuring data completeness (B) - confirming all expected forms and data files have been received.
Verifying coded data (A) - ensuring no pending terms remain in coding dictionaries like MedDRA or WHO Drug.
Performing SAE reconciliation (C) - cross-checking the clinical database against the safety system for accuracy.
However, ensuring study close-out visits (D) is not a data management function; it falls under clinical operations and monitoring responsibilities. While data management may review confirmation of site close-outs, the activity itself is not part of pre-database lock procedures.
Therefore, option D correctly identifies the exception-an activity outside the data manager's direct scope of responsibility before database closure.

Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Lock and Archiving, Section 5.3 - Pre-Lock Validation and Reconciliation Activities ICH E6(R2) GCP, Section 5.5.3 - Data Handling and Quality Control Prior to Lock FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.1 - Database Management and Lock Procedures

**NEW QUESTION: 21**
Which data are needed to monitor site variability in eligibility screening?
**A.** Number of sites with low enrollment
**B.** Number of subjects screened and number of subjects enrolled
**C.** Number of subjects enrolled
**D.** Number of sites with high enrollment
**Answer: B (LEAVE A REPLY)**
To monitor site variability in eligibility screening, you must analyze the number of subjects screened versus the number of subjects enrolled at each site. This allows identification of sites that are over- or under-screening relative to their enrollment yield.
The GCDMP (Chapter: Data Quality Assurance and Metrics) emphasizes that screening-to-enrollment ratios are critical indicators of protocol compliance and data quality. Sites with unusually low conversion rates may have unclear understanding of inclusion/exclusion criteria, requiring targeted training or monitoring.
Other options (A, C, D) provide enrollment metrics but do not reveal screening efficiency or variability, which depend on both screening and enrollment data.
Thus, option B correctly identifies the data necessary for monitoring eligibility screening performance across sites.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Quality Assurance and Metrics, Section 5.4 - Site Performance Metrics ICH E6(R2) GCP, Section 5.18 - Monitoring and Site Oversight Requirements

**NEW QUESTION: 22**
Which is the best way to identify sites with high subject attrition?
**A.** Proportion of patients for which two visit periods have passed without data by site
**B.** Number of late visits per site
**C.** Proportion of late visits by site
**D.** Number of patients for which two visit periods have passed without data
**Answer: A (LEAVE A REPLY)**
The best method to identify sites with high subject attrition is to calculate the proportion of patients for which two visit periods have passed without data, by site.
According to the GCDMP (Chapter: Data Quality Assurance and Control), subject attrition is an important performance indicator for data completeness and site compliance.

Evaluating missing or delayed data across multiple consecutive visit periods allows for early detection of potential dropouts or site-level operational issues.
By assessing this proportion at the site level, the Data Manager can distinguish between random missing data and systematic site underperformance. Counting or proportioning late visits (options B and C) identifies scheduling delays, not attrition. Looking at missing data without site context (option D) fails to identify site-specific patterns, limiting corrective action.
This metric aligns with risk-based monitoring (RBM) practices recommended by ICH E6 (R2) and FDA RBM Guidance, which promote proactive identification of sites at risk of data loss.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and Control, Section 5.4 - Site Performance Metrics ICH E6 (R2) Good Clinical Practice, Section 5.18 - Monitoring and Site Performance Evaluation FDA Guidance for Industry: Oversight of Clinical Investigations - Risk-Based Monitoring, Section 6 - Site Performance Metrics

**NEW QUESTION: 23**
What is the main reason 21 CFR Part 11 requires that EDC systems maintain an audit trail?
**A.** To preserve data integrity
**B.** To preserve the ability for modifications
**C.** To preserve source document verifications
**D.** To preserve data availability
**Answer: A (LEAVE A REPLY)**
The primary purpose of maintaining an audit trail as required under 21 CFR Part 11 is to preserve data integrity. According to the U.S. FDA's regulation on electronic records and signatures, every change to electronic data must be traceable, including information about who made the change, when it was made, and what the change entailed.
The Good Clinical Data Management Practices (GCDMP) outlines that an audit trail provides a permanent, chronological record of all modifications to clinical data. This ensures transparency and allows the reconstruction of the course of data entry and modification. The regulation aims to prevent unauthorized or undocumented data manipulation, thereby maintaining the accuracy, reliability, and validity of electronic records.
The FDA 21 CFR Part 11, Section 11.10(e) explicitly mandates that systems must use secure, computer-generated, time-stamped audit trails to independently record the date and time of operator entries and actions that create, modify, or delete electronic records. This ensures the data remains trustworthy and defensible in regulatory reviews or inspections.

Therefore, the main reason for requiring an audit trail is to preserve data integrity - ensuring that all data captured, modified, or transmitted is authentic, accurate, and complete throughout the study lifecycle.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Regulatory Compliance and Data Integrity FDA 21 CFR Part 11 - Electronic Records; Electronic Signatures, Section 11.10(e) ICH E6 (R2) Good Clinical Practice, Section 5.5.3 - Data Integrity and System Validation

**NEW QUESTION: 24**
What does 21 CFR Part 11 dictate in regards to a minimum expectation of EDC training prior to access?
**A.** Training must be performed
**B.** Training must include an exam
**C.** Training must be in the user's native language
**D.** Training must be face to face
**Answer: (SHOW ANSWER)**
Under FDA 21 CFR Part 11, organizations using electronic systems must ensure that all system users are trained to perform their assigned functions before gaining access to the system. The regulation requires documented evidence of training but does not specify how it should be conducted (e.g., exam-based, in person, or language-specific).
The GCDMP (Chapter: Computerized Systems and Compliance) further clarifies that personnel training should include instruction on system functionality, audit trails, data entry procedures, and electronic signatures to maintain compliance and data integrity. Training must be performed and documented but does not require a specific format or delivery method.
Therefore, option A-Training must be performed-is correct, as it reflects the minimum regulatory expectation per FDA and SCDM standards.
Reference (CCDM-Verified Sources):
FDA 21 CFR Part 11, Section 11.10(i) - Personnel Training Requirements
SCDM GCDMP, Chapter: Computerized Systems and Compliance, Section 5.4 - System Training and Documentation ICH E6(R2) GCP, Section 2.8 - Qualified Personnel and Training Requirements

**NEW QUESTION: 25**
A Data Manager is asked to manage SOPs for a department. Given equal availability of the following systems, which of the following is the best choice for managing the organizational SOPs?
**A.** Document management system
**B.** Customized Excel spreadsheet
**C.** Learning management system

**D.** Existing paper filing system

**Answer: A (LEAVE A REPLY)**

The best choice for managing Standard Operating Procedures (SOPs) in a compliant and auditable manner is a Document Management System (DMS).

According to the GCDMP (Chapter: Regulatory Requirements and Compliance) and ICH E6 (R2), SOPs must be version-controlled, securely stored, retrievable, and auditable. A validated DMS supports controlled access, document lifecycle management (draft, review, approval, and archival), and electronic audit trails, ensuring full compliance with FDA 21 CFR Part 11 and Good Documentation Practices (GDP).

While Learning Management Systems (C) track training, they are not intended for document control. Spreadsheets (B) and paper systems (D) cannot provide adequate version tracking, access security, or audit capability required for regulatory inspection readiness.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Regulatory Requirements and Compliance, Section 5.2 - SOP Management and Document Control ICH E6 (R2) GCP, Section 5.5.3 - Document and Record Management FDA 21 CFR Part 11 - Electronic Records and Signatures, Section 11.10 - System Validation and Document Controls

**NEW QUESTION: 26**

Which of the following is a best practice for creating eCRFs for a study?

**A.** Set up coded terms so they are available to the site user

**B.** Set up features that automatically enter data into fields when bypassed

**C.** Develop eCRFs with cross-functional team members

**D.** Develop eCRFs that closely follow paper CRF standards

**Answer: C (LEAVE A REPLY)**

The best practice for developing electronic Case Report Forms (eCRFs) is to involve cross-functional team members throughout the design process.

According to the GCDMP (Chapter: CRF Design and Data Collection), eCRFs should be collaboratively developed by data management, clinical operations, biostatistics, medical, and regulatory teams. Each function provides a unique perspective - data managers focus on data capture and validation; statisticians ensure alignment with analysis requirements; clinicians ensure medical relevance and protocol compliance.

Collaborative development ensures that the eCRFs are fit-for-purpose, capturing all required data accurately, minimizing redundancy, and supporting downstream data analysis.

Options A and B violate good data management practice because sites should not directly access coded terms (to prevent bias), and fields should never auto-populate without explicit source verification. Option D is outdated; while paper CRFs may inform structure, EDC-optimized eCRFs should leverage system functionality rather than mimic paper.

Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: CRF Design and Data Collection, Section 4.2 - Collaborative CRF Development ICH E6 (R2) GCP, Section 5.5.3 - Data Collection and System Validation FDA Guidance for Industry: Electronic Source Data in Clinical Investigations, Section 3.4 - CRF Design Considerations

**NEW QUESTION: 27**
A Data Manager is drafting a report for clinical operations staff for support in responding to questions about milestone-based site payments. Which is the most important information to display?
**A.** Milestones met by month, by site
**B.** Milestones met by month, by type
**C.** Expected versus actual milestones met to date, by site
**D.** Milestones included in the last payment by site, by patient
**Answer: (SHOW ANSWER)**
When reporting milestone-based site payment information, the most critical information to include is expected versus actual milestones met to date, by site.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Project Management and Communication), effective reporting must support operational and financial decision-making by presenting performance indicators in a clear, actionable format. Site payments in clinical studies are typically tied to specific milestones such as subject enrollment, visit completion, or data cleaning achievements.
By comparing expected (planned) versus actual (achieved) milestones per site, the Data Manager provides clinical operations staff with an accurate view of site progress and payment eligibility. This allows for identification of delayed sites, forecasting of upcoming payments, and early intervention for underperforming centers.
While milestone summaries by month or type (options A and B) may be useful for trend analysis, they lack the operational detail required for financial tracking. Milestone data by patient (option D) is overly granular for site-level payment management.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Project Management and Communication, Section 6.2 - Data Reporting for Site Performance and Payments ICH E6 (R2) Good Clinical Practice, Section 5.18.4 - Communication and Monitoring Reports FDA Guidance for Industry: Oversight of Clinical Investigations - Site Management and Reporting

**NEW QUESTION: 28**
A study has an expected enrollment period of one year but has subject recruitment issues. Twelve new sites are added toward the end of the expected enrollment period to help boost enrollment. What is the most likely impact on data flow?

**A.** The database set-up will need to be changed to allow for additional sites as they are added to the study.
**B.** The distribution of subjects selected for quality control will need to be stratified to allow for the twelve new sites.
**C.** A bolus of CRFs at the end of the study will result in the need to increase data entry and cleaning rates to meet existing timelines.
**D.** Additional sites will likely have increased query rates since site training is occurring closer to study close.
**Answer: C (LEAVE A REPLY)**
Adding multiple new sites late in the enrollment period creates a concentrated influx of new data near the end of the study. These sites typically start enrolling patients later, resulting in a "bolus" of Case Report Forms (CRFs) that must be entered, validated, and cleaned within a shorter timeframe to meet database lock deadlines.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Project Management and Data Flow), late site activation compresses the timeline for data management tasks, necessitating increased resources for data entry, query management, and cleaning. Data management teams must anticipate this surge and plan accordingly-either by increasing staffing or revising timelines to prevent bottlenecks and maintain quality.
While option D (increased query rates) can occur, it is a secondary effect. The most direct and consistent impact is the surge in data volume requiring expedited processing near study end.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Project Management, Section 5.3 - Managing Changes in Site Activation and Data Flow ICH E6(R2) GCP, Section 5.1 - Quality Management and Oversight

**NEW QUESTION: 29**
A site study coordinator attempts to make an update in a study database in an EDC system after lock. What occurs?
**A.** The old value is replaced in all locations by the new value
**B.** The change is approved by the Data Manager before it is applied
**C.** The site study coordinator is not able to make the change
**D.** The change is logged as occurring after lock
**Answer: C (LEAVE A REPLY)**
Once a clinical database is locked, it becomes read-only - no further data modifications can be made by any users, including site personnel. This ensures that the data are finalized, consistent, and auditable for statistical analysis and regulatory submission.
According to the GCDMP (Chapter: Database Lock and Archiving), the lock process involves freezing the database to prevent accidental or unauthorized changes. After lock, access permissions are restricted, and all edit and update functions are disabled. If any

corrections are required post-lock, the database must be unlocked under controlled procedures (with full audit trail documentation).
Thus, option C - The site study coordinator is not able to make the change - correctly reflects standard EDC functionality and regulatory compliance.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Lock and Archiving, Section 5.2 - Database Lock Procedures and Controls ICH E6(R2) GCP, Section 5.5.3 - Data Integrity and Audit Trail Requirements FDA 21 CFR Part 11 - Controls for Electronic Records and System Lock Functions

**NEW QUESTION: 30**
Which of the following is the best reason for a statistician to review the case report form prior to using it in a study?
**A.** To ensure the data from the CRF can be analyzed for safety and efficacy
**B.** To ensure the header fields will provide a unique key for each subject
**C.** To ensure the layout will make a logical, useful programming guide
**D.** To ensure the variable names conform to statistical programming standards
**Answer: A (LEAVE A REPLY)**
The primary reason a statistician reviews the Case Report Form (CRF) is to ensure that the data being collected will support the planned statistical analyses for both safety and efficacy endpoints.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: CRF Design and Data Collection), CRF design should always align with the statistical analysis plan (SAP) to ensure that all necessary data elements are collected accurately and in analyzable formats. The statistician verifies that the CRF captures:
All endpoints specified in the protocol
Proper derivation or calculation fields
Timing of assessments
Consistency across visits and forms
Options B, C, and D address secondary or technical design considerations but not the primary analytical purpose. The review ensures that the CRF provides a complete and analyzable dataset for meeting study objectives, regulatory submissions, and statistical integrity.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: CRF Design and Data Collection, Section 4.4 - Role of Statistics in CRF Design ICH E9 - Statistical Principles for Clinical Trials, Section 5.2 - Data Collection and Analysis Alignment FDA Guidance for Industry: E6(R2) GCP, Section 5.1 - Quality Management and Design Input from Stakeholders

**NEW QUESTION: 31**

Data characterizing the safety profile of a drug are collected to provide information for which of the following?

**A.** Survival curves

**B.** Efficacy meta-analyses

**C.** Product labeling

**D.** Quality of life calculations

**Answer: C (LEAVE A REPLY)**

Safety data collected during a clinical trial are used primarily to support product labeling, ensuring accurate communication of a drug's risks, contraindications, and adverse reactions to healthcare providers and patients.

According to the GCDMP (Chapter: Safety Data Handling and Reconciliation) and ICH E2A/E2F guidelines, all adverse events (AEs), serious adverse events (SAEs), and laboratory abnormalities are analyzed and summarized to define the safety profile of an investigational product. These data form the basis for regulatory submissions such as the Clinical Study Report (CSR) and product labeling (e.g., prescribing information), as required by the FDA and other regulatory authorities.

While safety data may contribute indirectly to analyses such as survival curves (option A) or quality of life metrics (option D), their primary regulatory function is to inform product labeling and post-marketing surveillance documentation.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Safety Data Handling and Reconciliation, Section 4.3 - Use of Safety Data in Regulatory Submissions

ICH E2A - Clinical Safety Data Management: Definitions and Standards for Expedited Reporting FDA Guidance for Industry: Adverse Event Reporting and Labeling Requirements

**Valid CCDM Dumps** shared by PrepPdf.com for Helping Passing CCDM Exam! PrepPdf.com now offer the **newest CCDM exam dumps**, the PrepPdf.com CCDM exam **questions have been updated** and **answers have been corrected** get the **newest** PrepPdf.com CCDM dumps with Test Engine here: https://www.preppdf.com/SCDM/CCDM-prepaway-exam-dumps.html (**152** Q&As Dumps, **40%OFF** **Special Discount:** **Exam-Tests**)

**NEW QUESTION: 32**

A protocol amendment adds three data elements to the vital signs screen and two additional data-collection time points. Which is best practice for handling changes to the form completion guidelines?

**A.** Update the guidelines and notify sites of changes prior to implementing the change

**B.** Update the guidelines and post the new version on the trial portal

**C.** Rely on the revised CRF to enforce the changes without updating guidelines or notifying sites
**D.** Notify sites of the change without a guideline update
**Answer: (SHOW ANSWER)**
The best practice when implementing a protocol amendment that affects CRF content or data collection timing is to update the eCRF completion guidelines and notify sites before implementing the change.
According to the GCDMP (Chapter: CRF Design and Data Collection), the eCRF Completion Guidelines (eCRF CG) are an essential study tool that instructs site personnel on accurate and consistent data entry. When new data elements or collection time points are added, the guidelines must be revised, version-controlled, and communicated to all users prior to implementation to ensure sites collect and enter data correctly.
Simply relying on the revised CRF (option C) or updating the document without notification (option B) violates communication and training standards. Likewise, notifying sites without updating the documentation (option D) leaves insufficient reference material for data entry compliance.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: CRF Design and Data Collection, Section 5.5 - Managing CRF Revisions and Site Communication ICH E6 (R2) GCP, Section 5.18.4 - Communication of Protocol Amendments and Documentation Updates FDA Guidance for Industry: Electronic Source Data in Clinical Investigations, Section 4.3 - Site Communication and Documentation Management

**NEW QUESTION: 33**
Which statement applies to the CRF Completion Guidelines (CCGs) for a multinational study?
**A.** CCGs must be translated and back-translated in each local language used in the study
**B.** CCGs must contain the list of acceptable abbreviations to be used in the CRF
**C.** CCGs can instruct sites to write in their local language as long as the CRA is fluent in this language
**D.** CCGs can instruct sites to use any abbreviations if they are documented in the subject source notes
**Answer: (SHOW ANSWER)**
The Case Report Form (CRF) Completion Guidelines (CCGs) are critical documents that guide site staff on how to accurately and consistently record data on CRFs across all participating sites, especially in multinational trials.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: CRF Design and Data Collection), one of the key components of the CCGs is a list of acceptable abbreviations and conventions to be used during CRF entry. This standardization ensures data consistency across languages and countries, reduces ambiguity during data review, and facilitates database design and coding accuracy.

While translation (A) may be useful for training materials, it is not required for CCGs unless specified by regulatory bodies. Options C and D are incorrect because data collection should adhere to standardized terms in English (or the study's official language) - allowing free use of local languages or arbitrary abbreviations introduces inconsistencies.
Hence, option B - "CCGs must contain the list of acceptable abbreviations to be used in the CRF" - is correct.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: CRF Design and Data Collection, Section 5.3 - CRF Completion Guidelines and Standardization ICH E6(R2) GCP, Section 5.5.3 - Consistency and Data Recording Requirements FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.2 - Data Entry Conventions and Documentation

**NEW QUESTION: 34**
What is the purpose of providing the central laboratory vendor with a complete listing of subjects' demographic data?
**A.** To provide for an independent reconciliation of the patient and remote databases after database lock
**B.** To assure that all subjects have lab data for valid visits
**C.** To provide for an independent reconciliation of the patient and remote databases during study conduct
**D.** To assure that lab data for screening failure subjects have not been included in the lab data transmission
**Answer: C (LEAVE A REPLY)**
Providing the central laboratory vendor with a complete subject demographic listing allows ongoing reconciliation between the sponsor's EDC system and the vendor's laboratory database during study conduct.
The GCDMP (Chapter: External Data Transfers and Integration) emphasizes that subject reconciliation ensures that all laboratory data correspond to valid enrolled subjects and visits. Regular reconciliation throughout the study prevents data mismatches, missing results, or misassigned lab reports.
This proactive measure supports timely query resolution and data integrity across systems. Waiting until after database lock (as in option A) would delay corrections and risk inconsistencies. Options B and D address secondary benefits but not the primary purpose-ongoing subject-level reconciliation.
Thus, option C is correct.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: External Data Transfers, Section 4.4 - Reconciliation and Vendor Communication ICH E6(R2) GCP, Section 5.5.3 - Data Management, Reconciliation, and Integration FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.3 - External Data Management

**NEW QUESTION: 35**
A Clinical Data Manager reads a protocol for a clinical trial to test the efficacy of an antiviral to counteract a new epidemic. The stated primary efficacy endpoint is 3-month survival. Which data element is needed for the primary efficacy endpoint?
**A.** Death date
**B.** Date of autopsy
**C.** Cause of death
**D.** Birth date
**Answer: A (LEAVE A REPLY)**
When the primary efficacy endpoint in a clinical trial is 3-month survival, the key data element required is the death date. This is because the survival endpoint is determined by calculating whether the subject lived or died within a defined time frame from study enrollment or randomization.
According to the GCDMP (Chapter: Data Management Planning and Study Start-up), the Clinical Data Manager (CDM) must identify and ensure the capture of all critical data elements necessary to evaluate the study endpoints. For time-to-event analyses (e.g., survival studies), accurate event dates (death date) are essential for endpoint derivation and statistical analysis.
Other data elements such as cause of death or date of autopsy (options B and C) may support secondary analyses or safety reviews but are not necessary to determine the survival endpoint itself. Similarly, birth date (option D) contributes to demographic data but is unrelated to the primary efficacy outcome.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Management Planning and Study Start-up, Section 4.4 - Critical Data Identification for Endpoints ICH E9 - Statistical Principles for Clinical Trials, Section 2.2.3 - Time-to-Event Data Considerations FDA Guidance for Industry: Clinical Trial Endpoints for Drug Development

**NEW QUESTION: 36**
Which list should be provided to support communication with sites regarding late data and queries?
**A.** List of entered and clean data by site
**B.** List of subjects screened and enrolled by site
**C.** List of user account activity by site
**D.** List of outstanding data and queries by site
**Answer: (SHOW ANSWER)**
Effective site communication in data management relies on transparent reporting of pending issues such as open queries, missing data, and overdue updates. According to the Good Clinical Data Management Practices (GCDMP, Chapter: Communication and Metrics), the list of outstanding data and queries by site provides a direct, actionable

overview of what each site needs to address, supporting accountability and timely resolution.
This list typically includes subject identifiers, query types, dates generated, and status of resolution, allowing data managers to prioritize site follow-ups. Regular distribution of this report fosters efficient collaboration between the data management team, monitors, and site staff, ultimately improving database cleanliness and timeline adherence.
Options A and B reflect general study status but do not target data issue resolution. Option C pertains to user access oversight, not data progress. Hence, option D is the correct and most operationally relevant answer.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Communication and Metrics, Section 5.2 - Site Reporting and Query Management Metrics ICH E6(R2) GCP, Section 5.18 - Site Oversight and Communication Requirements

**NEW QUESTION: 37**
Which protocol section best defines data needed for the primary study analysis?
**A.** Study schedule of events
**B.** Study endpoints section
**C.** Protocol synopsis
**D.** ICH essential documents
**Answer: (SHOW ANSWER)**
The study endpoints section of the protocol best defines the data required for the primary study analysis.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Data Management Planning and Study Start-up), the endpoint section specifies the critical efficacy and safety variables upon which the study's success criteria are based. These endpoints directly determine what data elements must be collected, validated, and analyzed. For example, if the primary endpoint is "change in systolic blood pressure from baseline to week 12," then data collection must include baseline and week 12 systolic blood pressure values and corresponding timepoints.
The schedule of events (option A) lists when data are collected but not their analytical relevance. The protocol synopsis (option C) provides a summary, while the ICH essential documents (option D) refer to trial documentation standards, not endpoint specifications. Thus, the study endpoints section defines the core analytical data requirements for clinical data managers, biostatisticians, and programmers.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Management Planning and Study Start-up, Section 5.2 - Defining Data Needed for Endpoints ICH E6 (R2) Good Clinical Practice, Section 6.3 - Trial Objectives and Endpoints FDA Guidance for Industry: Clinical Trial Endpoints for Drug Development and Approval

**NEW QUESTION: 38**
What does RACI stand for?
**A.** Responsible, Accountable, Contribute, Input
**B.** Recommend, Approve, Calibrate, Innovate
**C.** Responsibility, Accountability, Consultation, Information
**D.** Responsible, Accountable, Consulted, Informed
**Answer: D (LEAVE A REPLY)**
RACI is a project management and governance framework used to define roles and responsibilities within a project. Each letter represents a distinct role type:
Responsible (R): The person(s) who perform the work or execute the task.
Accountable (A): The individual ultimately answerable for the task's completion and success (only one per activity).
Consulted (C): Subject matter experts who provide input or guidance before decisions are made.
Informed (I): Individuals kept up to date on progress or outcomes but not directly involved in execution.
The RACI model ensures clarity in ownership and accountability, preventing duplication of effort or responsibility confusion. It is a key component of the GCDMP (Chapter: Project Management in Data Management) for ensuring clear delegation and communication within clinical data management teams.
Hence, option D is correct.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Project Management in Data Management, Section 5.1 - Roles, Responsibilities, and RACI Matrices Project Management Institute (PMI) Framework - Responsibility Assignment Matrices (RACI) ICH E6(R2) GCP, Section 5.1.1 - Defined Roles and Quality Oversight Responsibilities

**NEW QUESTION: 39**
Which Clinical Study Report section would be most useful for a Data Manager to review?
**A.** Clinical narratives of adverse events
**B.** Enumeration and explanation of data errors
**C.** Description of statistical analysis methods
**D.** Rationale for the study design
**Answer: B (LEAVE A REPLY)**
The section of the Clinical Study Report (CSR) that is most useful for a Data Manager is the one that includes the enumeration and explanation of data errors. This section provides a summary of the data quality control findings, including error rates, missing data summaries, and any issues identified during data review, validation, or database lock.
According to the GCDMP (Chapter: Data Quality Assurance and Control), post-study reviews of data errors and quality findings are essential for evaluating process

performance, identifying recurring issues, and informing continuous improvement in future studies.
Other sections, such as clinical narratives (A) or statistical methods (C), are outside the core scope of data management responsibilities. The data error enumeration section directly reflects the quality and integrity of the data management process and is therefore the most relevant for review.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Quality Assurance and Control, Section 6.4 - Quality Reporting and Error Analysis ICH E3 - Structure and Content of Clinical Study Reports, Section 14.3 - Data Quality Evaluation

**NEW QUESTION: 40**
Which of the following scenarios requires a query to be sent to the central lab first when there is a discrepancy between the final lab data transfer and the CRF?
**A.** Both the central lab and the CRF have data present for a visit
**B.** The CRF has data for a visit but the central lab has missing data for the visit
**C.** The central lab has data for a visit but the CRF has missing data for the visit
**D.** Both the central lab and the CRF data have missing data for a visit
**Answer: C (LEAVE A REPLY)**
During data reconciliation between a central laboratory and CRF data, the source of truth is typically the central lab database, as it provides directly measured, vendor-generated results.
When the central lab has data but the CRF does not (option C), the Data Manager must first query the central lab to confirm that the result was transmitted correctly, since discrepancies may stem from data processing or timing issues. Once confirmed, a secondary query may be issued to the site to ensure CRF completion and alignment.
Conversely, if the CRF contains data but the central lab is missing results (option B), the issue is site-level, not vendor-level.
According to the GCDMP (Chapter: External Data Transfers and Reconciliation), priority for querying depends on the authoritative source - for lab data, the central lab is considered the source of record.
Therefore, option C is correct.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: External Data Transfers and Reconciliation, Section 6.1 - Reconciliation of Central Lab and CRF Data ICH E6(R2) GCP, Section 5.5.3 - Source Data Verification and Vendor Reconciliation FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.4 - Data Reconciliation and Traceability

**NEW QUESTION: 41**
QA is conducting an audit on a study for ophthalmology which is ready for lock. Inconsistencies are found between the database and the source. Of the identified fields

containing potential data errors, which fields are considered critical for this particular study?

**A.** Subject Identifier

**B.** Concomitant Medications

**C.** Weight

**D.** Medical History

**Answer: B (LEAVE A REPLY)**

In an ophthalmology clinical study, data criticality is determined by how directly a data element affects safety evaluation, efficacy assessment, and regulatory decision-making. According to the Good Clinical Data Management Practices (GCDMP, Chapter on Data Validation and Cleaning), critical data fields are those that:

Have a direct impact on the primary and secondary endpoints, or

Are essential for safety interpretation and adverse event causality assessment.

Among the listed options, Concomitant Medications (Option B) are considered critical data for ophthalmology studies. This is because many ocular treatments and investigational products can interact with systemic or topical medications, potentially affecting ocular response, intraocular pressure, corneal healing, or visual function outcomes. Any inconsistency in concomitant medication data could directly influence safety conclusions or efficacy interpretations.

Other options, while important, are less critical for this study type:

Subject Identifier (A) is essential for data traceability and audit purposes but is not directly related to safety or efficacy outcomes.

Weight (C) may be relevant in dose-dependent drug trials but is rarely a pivotal variable in ophthalmology, where local administration (eye drops, intraocular injections) is common.

Medical History (D) provides contextual background but does not have the same immediate impact on endpoint analysis as current concomitant treatments that can confound the therapeutic effect or cause ocular adverse events.

Per GCDMP and ICH E6 (R2) GCP guidelines, data validation plans must define critical data fields during study setup, reflecting therapeutic area-specific priorities. For ophthalmology, concomitant medications, ocular assessments (visual acuity, intraocular pressure, retinal thickness, etc.), and adverse events are typically designated as critical fields requiring heightened validation, source verification, and reconciliation accuracy before database lock.

Thus, when QA identifies discrepancies between the CRF and source, the Concomitant Medications field (Option B) is the most critical to address immediately to ensure clinical and regulatory data integrity.

Reference (CCDM-Verified Sources):

Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 6.4 - Critical Data Fields and Data Validation Prioritization ICH E6 (R2) Good Clinical Practice, Section 5.18 - Monitoring and Source Data Verification FDA Guidance for Industry: Oversight of Clinical

Investigations - A Risk-Based Approach to Monitoring, Section 5.3 - Identification of Critical Data and Processes SCDM GCDMP Chapter: Data Quality Assurance and Control - Therapeutic Area-Specific Data Criticality Examples (Ophthalmology Studies)

**NEW QUESTION: 42**
Data from two sites are combined. One site coded gender as 1 and 2 (for Male and Female, respectively) while the other stored the data as M and F. Which term best describes the mapping?
**A.** Two-to-two
**B.** One-to-many
**C.** Many-to-one
**D.** One-to-one
**Answer: D (LEAVE A REPLY)**
When combining data from two datasets where one uses numeric codes (1 = Male, 2 = Female) and another uses text codes (M, F), each unique value in one dataset corresponds exactly to one unique value in the other.
This relationship is a one-to-one mapping, where each element in one dataset maps directly to a single corresponding element in the other.
1 → M
2 → F
Such mappings ensure consistent data harmonization during data integration and standardization phases, as outlined in the GCDMP (Chapter: Database Design and Integration).
Many-to-one (C) mapping would occur if multiple values (e.g., "Male," "M," "Man") mapped to a single standardized value, which isn't the case here.
Thus, the mapping is one-to-one, ensuring precise correspondence between both representations of gender data.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Design and Build, Section 5.4 - Data Mapping and Harmonization CDISC SDTM Implementation Guide, Section 5.2 - Controlled Terminology and Mapping Rules ICH E6(R2) GCP, Section 5.5.3 - Data Integrity and Integration Principles

**NEW QUESTION: 43**
Which competency is necessary for EDC system use in a study using the medical record as the source?
**A.** Screening study subjects
**B.** Using ePRO devices
**C.** Resolving discrepant data
**D.** Training on how to log into Medical Records system
**Answer: D (LEAVE A REPLY)**

In studies where the medical record serves as the source document, the Electronic Data Capture (EDC) system users (typically study coordinators or site personnel) must have appropriate training on how to access and log into the medical record system. This competency ensures that data abstracted from the electronic medical record (EMR) are complete, accurate, and verifiable in compliance with Good Clinical Practice (GCP) and Good Clinical Data Management Practices (GCDMP).
According to the GCDMP (Chapter: EDC Systems and Data Capture) and ICH E6(R2), all personnel involved in data entry and verification must be trained in both the EDC and the primary source systems (e.g., EMR). This ensures that the integrity of data flow-from source to EDC-is maintained, and that personnel understand system access controls, audit trails, and proper documentation of source verification.
While resolving discrepant data (C) and screening subjects (A) are part of study operations, the competency directly related to EDC system use in EMR-based studies is the ability to properly log into and navigate the medical records system to extract source data.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Electronic Data Capture (EDC), Section 5.1 - Source Data and System Access Requirements ICH E6(R2) Good Clinical Practice, Section 4.9 - Source Documents and Data Handling FDA Guidance: Use of Electronic Health Record Data in Clinical Investigations, Section 3 - Investigator Responsibilities

**NEW QUESTION: 44**
Which of the following actions is particularly important in merging data from different trials?
**A.** Use of a common software platform
**B.** Enrollment of investigative sites with similar patient populations
**C.** Exclusion of studies that use a cross-over design
**D.** Use of a common adverse event dictionary
**Answer: D (LEAVE A REPLY)**
When merging data from different clinical trials, the use of a common adverse event (AE) dictionary (such as MedDRA or WHO Drug) is essential to ensure consistency and comparability across datasets.
According to the GCDMP (Chapter: Standards and Data Mapping) and CDISC SDTM Implementation Guide, data integration across studies requires standardized terminology for adverse events, medications, and clinical outcomes. Using the same AE dictionary ensures that similar terms are coded consistently, allowing accurate cross-study analysis, pooled summaries, and safety reporting.
A shared software platform (option A) is not necessary if data are mapped to standard formats (e.g., CDISC SDTM). Patient population similarity (option B) affects interpretation but not technical data merging. Study design differences (option C) may influence statistical analysis but not data integration mechanics.

Therefore, Option D - Use of a common adverse event dictionary - is the correct and most critical action for consistent multi-study data integration.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Standards and Data Mapping, Section 5.1 - Use of Standardized Coding Dictionaries CDISC SDTM Implementation Guide, Section 4.3 - Controlled Terminology and Cross-Study Integration ICH E3 and E2B - Clinical Data Standards and Safety Coding Requirements

**NEW QUESTION: 45**
A group of researchers is planning an investigator-initiated study. Assuming that SOPs are not available, which is the best approach for documentation of data management in the planned study?
**A.** Data handling should be documented in a data management plan
**B.** Data management SOPs must be developed prior to initiation of study
**C.** A Data Management Plan (DMP) template should be developed and a study DMP should be created
**D.** Data management related activities should be briefly described in the study protocol
**Answer: (SHOW ANSWER)**
In the context of an investigator-initiated trial (IIT) where Standard Operating Procedures (SOPs) are not available, the most appropriate and compliant approach is to develop a Data Management Plan (DMP) template and then create a study-specific DMP based on that template (Option C).
According to the Good Clinical Data Management Practices (GCDMP, Chapter on Data Management Planning and Study Start-up), the DMP is the central document that defines all processes, responsibilities, systems, and quality controls related to data collection, processing, validation, and database management throughout the clinical study. The DMP serves as a formal framework for ensuring data integrity, traceability, and regulatory compliance, especially in the absence of established institutional SOPs.
While SOPs provide organizational-level standards, the DMP provides study-specific operational detail. In an investigator-initiated setting, researchers often lack institutional data management infrastructure, so the DMP must substitute for SOP guidance by detailing:
Data entry and validation procedures
Query management and resolution processes
CRF design and data flow specifications
Database design, backup, and security
Responsibilities of study personnel (investigator, data manager, statistician) Quality control and audit trail practices Option A ("Data handling should be documented in a DMP") is correct in principle but incomplete-without a DMP template, there is no standardized format or consistency across studies.

Option B (developing full SOPs) is not practical for a single IIT; SOPs are organizational-level documents requiring longer development and approval cycles.
Option D (briefly describing data management in the protocol) is insufficient, as the protocol should reference data management activities but not serve as the operational manual for them.
Therefore, Option C provides the most comprehensive, regulatory-compliant, and practical solution-ensuring structured documentation of all data management activities while maintaining flexibility for investigator-led research.
Reference (CCDM-Verified Sources):
Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP), Chapter: Data Management Planning and Study Start-up, Section 5.2 - Data Management Plan (DMP) Development and Maintenance ICH E6 (R2) Good Clinical Practice, Section 5.1 - Quality Management and Documentation Requirements FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 4 - Data Management and Documentation Practices SCDM GCDMP, Chapter: Project Management in Data Management - Study-Specific Documentation and Planning in Investigator-Initiated Trials

**NEW QUESTION: 46**
Which of the following laboratory findings is a valid adverse event reported term that facilitates auto coding?
**A.** Elevated HDL
**B.** ALT
**C.** Abnormal SGOT
**D.** Increased alkaline phosphatase, increased SGPT, increased SGOT, and elevated LDH
**Answer: A (LEAVE A REPLY)**
When coding adverse events (AEs) using MedDRA (Medical Dictionary for Regulatory Activities), valid AE terms must correspond to specific, medically meaningful concepts that match directly to a Preferred Term (PT) or Lowest Level Term (LLT) in the dictionary.
Among the options, "Elevated HDL" (High-Density Lipoprotein) represents a single, medically interpretable, and standard term that can directly match to a MedDRA LLT or PT. This makes it suitable for auto-coding, where the system automatically maps verbatim terms to MedDRA entries without manual intervention.
In contrast:
ALT (B) and Abnormal SGOT (C) are incomplete or nonspecific; they describe test names or qualitative interpretations rather than events.
Option D lists multiple findings, making it too complex for automatic mapping. Such compound entries would require manual coding review.
According to GCDMP (Chapter: Medical Coding and Dictionaries), a valid AE term should be:
Clinically interpretable (not just a lab test name)

Unambiguous
Single-concept based, not a collection of results
Thus, option A (Elevated HDL) is correct, as it aligns with MedDRA's single-concept, standard terminology structure suitable for auto-coding.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Medical Coding and Dictionaries, Section 5.3 - Auto-coding and Verbatim Term Management ICH M1 MedDRA Term Selection: Points to Consider, Section 2.1 - Coding Principles ICH E2B(R3) - Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports

**Valid CCDM Dumps** shared by PrepPdf.com for Helping Passing CCDM Exam! PrepPdf.com now offer the **newest CCDM exam dumps**, the PrepPdf.com CCDM exam **questions have been updated** and **answers have been corrected** get the **newest** PrepPdf.com CCDM dumps with Test Engine here: https://www.preppdf.com/SCDM/CCDM-prepaway-exam-dumps.html (**152** Q&As Dumps, **40%OFF** **Special Discount:** **Exam-Tests**)

**NEW QUESTION: 47**
Which information should be communicated by the Data Manager at regular intervals throughout a study?
**A.** Planned versus actual enrollment
**B.** Site staffing changes
**C.** Percent data entered and clean
**D.** Serious and unexpected safety events
**Answer: C (LEAVE A REPLY)**
The Data Manager (DM) plays a critical role in maintaining transparent communication with the clinical study team regarding data quality and study progress. One of the most essential metrics regularly reported by the DM is the percentage of data entered and cleaned.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Communication and Study Reporting), these metrics provide insight into study status, data readiness for interim analysis, and timeline predictability for database lock. Regular communication includes:
Percent of CRFs entered and verified
Percent of queries resolved
Outstanding data issues or missing pages
Other options fall outside the Data Manager's direct responsibility:
A (Enrollment) is typically reported by clinical operations.
B (Staffing changes) are handled by site management.

D (Safety events) are communicated by the safety/pharmacovigilance team.
Thus, option C correctly reflects the Data Manager's responsibility for ongoing study communication.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Communication and Study Reporting, Section 5.3 - Study Metrics and Status Updates ICH E6(R2) GCP, Section 5.1.1 - Communication and Oversight in Quality Management FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.5 - Data Status Reporting

**NEW QUESTION: 48**
An astute monitor discovers that a site is using nebulized albuterol rather than the inhaler provided in the study screening kit for the albuterol challenge. Which is the best response from the Data Manager?
**A.** No response is needed, the problem does not impact data
**B.** Contact the Ethics Committee
**C.** Update the CRF Completion Guidelines and notify all sites of the update
**D.** Query the site to enter a Protocol Violation
**Answer: D (LEAVE A REPLY)**
In this scenario, the site has deviated from the approved study protocol by using a different formulation (nebulized albuterol instead of inhaler). This is considered a protocol deviation or violation, depending on study definitions.
Per GCDMP (Chapter: Data Validation and Cleaning) and ICH E6(R2), Data Managers are responsible for ensuring that all protocol deviations affecting data integrity or subject safety are accurately captured and documented within the clinical database. The appropriate action is to issue a data query prompting the site to record the deviation in the designated section (e.g., "Protocol Deviations" CRF).
Option A: Incorrect - it affects data comparability.
Option B: Escalation to the Ethics Committee is handled by the sponsor, not the Data Manager.
Option C: Updating the CRF guidelines is premature; first, the deviation must be logged and assessed.
Therefore, option D (Query the site to enter a Protocol Violation) is the correct and compliant action.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Validation and Cleaning, Section 6.2 - Query Management and Protocol Deviations ICH E6(R2) GCP, Section 4.5 - Compliance with Protocol FDA Guidance for Industry: Oversight of Clinical Investigations - Compliance and Protocol Deviation Reporting

**NEW QUESTION: 49**

During an inspection to determine appropriate documentation for use of a computerized system, what SOP might the inspector expect to find?

**A.** Data management plan

**B.** Data backup plan

**C.** Statistical analysis plan

**D.** Edit specifications

**Answer: (SHOW ANSWER)**

During a regulatory inspection, inspectors expect to find documented Standard Operating Procedures (SOPs) governing the use, validation, and maintenance of computerized systems, including data backup and recovery procedures.

According to the GCDMP (Chapter: Computerized Systems and Compliance) and FDA 21 CFR Part 11, organizations must maintain an SOP that ensures data protection against loss, corruption, or unauthorized access. The SOP should describe backup frequency, secure storage, verification of backup integrity, and procedures for data restoration.

While the Data Management Plan (A) and Edit Specifications (D) are study-level documents, and the Statistical Analysis Plan (C) focuses on analysis procedures, only a Data Backup Plan (B) constitutes a required system-level SOP ensuring compliance and data continuity.

Reference (CCDM-Verified Sources):

SCDM GCDMP, Chapter: Computerized Systems and Compliance, Section 5.2 - Data Security, Backup, and Recovery SOPs FDA 21 CFR Part 11 - Subpart B, Controls for Closed Systems ICH E6(R2) GCP, Section 5.5.3 - System Security, Data Backup, and Recovery Requirements

**NEW QUESTION: 50**

An asthma study is taking into account local air quality and receives that data from the national weather bureau. Which information is needed to link research subject data to the air-quality readings?

**A.** Location identifier

**B.** Location and time identifiers

**C.** Location, time and subject identifiers

**D.** Location, time, subject and site identifiers

**Answer: (SHOW ANSWER)**

When integrating external environmental data such as air quality readings with clinical study data, it is essential to use location and time identifiers to properly align the environmental data with subject-level data.

According to the Good Clinical Data Management Practices (GCDMP, Chapter: Data Management Planning and Study Start-up), external data sources (like national weather or pollution databases) must be merged using common linkage variables that allow synchronization without breaching subject confidentiality. In this case:

Location identifiers (e.g., city, postal code, or region) align the subject's study site or residential area with the environmental dataset.
Time identifiers (e.g., date and time of data collection) ensure that the environmental readings correspond to the same period as the subject's clinical observations.
Including subject identifiers (option C or D) is unnecessary and would pose privacy and data protection risks. Instead, linkage is typically done at the aggregate (site or regional) level, maintaining compliance with HIPAA and GDPR.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Integration and External Data Handling, Section 4.3 - Linking External Data Sources ICH E6 (R2) GCP, Section 5.5.3 - Data Traceability and External Data Management FDA Guidance for Industry: Use of Electronic Health Record Data in Clinical Investigations, Section 5.2 - Linking and Integration Principles

**NEW QUESTION: 51**
Which is the MOST appropriate flow for EDC set-up and implementation?
**A.** CRF "wire-frames" created, CRFs reviewed, CRFs printed, CRFs distributed to sites
**B.** Protocol finalized, Database created, Edit Checks created, Database tested, Sites trained
**C.** Database created, Subjects enrolled, Database tested, Sites trained, Database released
**D.** Database created, Database tested, Sites trained, Protocol finalized, Database released
**Answer: (SHOW ANSWER)**
The correct and compliant sequence for EDC system setup and implementation begins only after the study protocol is finalized, as all case report form (CRF) designs, database structures, and validation rules derive directly from the finalized protocol.
According to GCDMP (Chapter: EDC Systems Implementation), the proper order is:
Protocol finalized - defines endpoints and data requirements.
Database created - built according to the protocol and CRFs.
Edit checks created - programmed to validate data entry accuracy.
Database tested (UAT) - ensures functionality, integrity, and compliance.
Sites trained and system released - only then can data entry begin.
Option B follows this logical and regulatory-compliant sequence. Other options (A, C, D) are either paper-based workflows or violate GCP-compliant timelines (e.g., enrolling subjects before database validation).
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Electronic Data Capture (EDC) Systems, Section 5.2 - System Setup and Implementation Flow ICH E6(R2) GCP, Section 5.5.3 - Computerized Systems Validation and User Training Before Use FDA 21 CFR Part 11 - Validation and System Release Requirements

**Valid CCDM Dumps** shared by PrepPdf.com for Helping Passing CCDM Exam! PrepPdf.com now offer the **newest CCDM exam dumps**, the PrepPdf.com CCDM exam **questions have been updated** and **answers have been corrected** get the **newest** PrepPdf.com CCDM dumps with Test Engine here: https://www.preppdf.com/SCDM/CCDM-prepaway-exam-dumps.html (**152** Q&As Dumps, **40%OFF** **Special Discount:** **Exam-Tests**)